AbbVie to expand immunology pipeline with Nimble Therapeutics acquisition

Pallavi Madhiraju- December 14, 2024 0

In a significant move to solidify its presence in immunology, AbbVie has announced the acquisition of Nimble Therapeutics, a company at the forefront of peptide-based ... Read More

Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments

Pallavi Madhiraju- August 18, 2024 0

Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory ... Read More

Eli Lilly’s mirikizumab triumphs in Phase 3 Crohn’s disease study

Pallavi Madhiraju- October 14, 2023 0

Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated its prowess against placebo in the critical ... Read More

Eli Lilly completes $2.4bn acquisition of DICE Therapeutics

Pallavi Madhiraju- August 10, 2023 0

Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion ... Read More

Aeglea BioTherapeutics buys Spyre Therapeutics to revolutionize IBD treatment

Pallavi Madhiraju- June 25, 2023 0

Aeglea BioTherapeutics, a Nasdaq-listed company, has acquired Spyre Therapeutics, a private biotech company dedicated to advancing a promising pipeline of antibody therapeutics aimed at revolutionizing ... Read More

Lilly to acquire biopharma company DICE Therapeutics in $2.4bn deal

Pallavi Madhiraju- June 20, 2023 0

Eli Lilly and Company (Lilly) has agreed to acquire US-based biopharmaceutical company DICE Therapeutics, listed on the Nasdaq, in an all-cash deal worth $2.4 billion. ... Read More

Roivant Sciences, Pfizer create new business for inflammatory disease drug

Raghuram Kadari- December 3, 2022 0

Roivant Sciences, a US healthcare company, and Pfizer have established a new Vant to develop and commercialize PF-06480605 (now RVT-3101) for inflammatory and fibrotic bowel ... Read More

Seres Therapeutics begins Phase 1b trial for SER-301 in active ulcerative colitis

pharmanewsdaily- November 8, 2020 0

Seres Therapeutics, a prominent US-based biotech company, has announced the commencement of dosing in a Phase 1b clinical trial for SER-301, a novel microbiome-based therapeutic ... Read More

Bristol Myers Squibb’s Zeposia shows promising results in phase 3 True North trial for ulcerative colitis treatment

pharmanewsdaily- October 11, 2020 0

Bristol Myers Squibb (BMS) has reported significant success in its phase 3 True North clinical trial, evaluating the efficacy of Zeposia (ozanimod) as an oral ... Read More

Gilead Sciences, Second Genome form IBD drug discovery alliance

pharmanewsdaily- April 9, 2020 0

Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates ... Read More

1210 / 11 Posts